Systemic increase of AMPA receptors associated with cognitive impairment of long COVID, 2025, Fujimoto et al.

SNT Gatchaman

Senior Member (Voting Rights)
Staff member
Systemic increase of AMPA receptors associated with cognitive impairment of long COVID
Fujimoto, Yu; Abe, Hiroki; Eiro, Tsuyoshi; Tsugawa, Sakiko; Tanaka, Meiro; Hatano, Mai; Nakajima, Waki; Ichijo, Sadamitsu; Arisawa, Tetsu; Takada, Yuuki; Kimura, Kimito; Sano, Akane; Hirahata, Koichi; Sasaki, Nobuyuki; Kimura, Yuichi; Takahashi, Takuya

Long COVID primarily presents with persistent cognitive impairment (Cog-LC), imposing a substantial and lasting global burden. Even after the pandemic, there remains a critical global need for diagnostic and therapeutic strategies targeting Cog-LC. Nevertheless, the underlying neural mechanisms remain poorly understood. Given the central role of synapses in brain function, investigation of synaptic molecular changes may provide vital insights into Cog-LC pathophysiology.

In this study, we used [11C]K-2 PET to characterize the density of AMPA receptors (AMPARs) on the post-synaptic cell surface, which are crucial synaptic components in brain signalling. Statistical parametrical mapping was used to spatially normalize and apply independent t-test for a voxel-based comparison. We selected patients with Cog-LC (n = 30) based on Repeatable Battery for the Assessment of Neuropsychological Status assessed persistent cognitive impairment and healthy controls (n = 80) with no diagnosed neuropsychiatric disorders. The primary objective was to compare [11C]K-2 standardized uptake value ratio with white matter (SUVRWM) as a reference region between patients with Cog-LC and healthy controls, and to define the regional extent of differences. The secondary objective was to examine associations between [11C]K-2 SUVRWM and plasma concentrations of cytokines or chemokines. As an exploratory objective, we tested whether [11C]K-2 PET data could distinguish Cog-LC from healthy controls using a partial least squares based classification algorithm.

A voxel-based comparison (P < 0.05, T > 1.66, one-tailed, false discovery rate control) and a volume of interests analysis (P < 0.05, Bonferroni multiple comparison) demonstrated that increased index of AMPAR density in large parts of the brains of patients with Cog-LC compared with that in healthy controls. A voxel-based correlation analysis also showed the brain regions where [11C]K-2 SUVRWM correlated positively with plasma TNFSF12 and negatively with plasma CCL2 concentrations. A partial least squares model trained on the index of AMPAR density data demonstrated high diagnostic accuracy, achieving 100% sensitivity and 91.2% specificity. [11C]K-2 PET signal represents the index of AMPAR density on the post-synaptic neural cell surface, not on the glial cell surface.

A systemic increase in synaptic AMPARs across the brain may drive abnormal information processing in Cog-LC and, through excessive excitatory signalling, pose a risk of excitotoxic neuronal damage. We derived the hypothesis that [11C]K-2 PET would be helpful in establishing a diagnostic framework for Cog-LC and that antagonists for cell surface AMPARs, such as perampanel, would be a potential therapeutic target. These hypotheses should be investigated in future large-scale clinical studies.

Web | PDF | Brain Communications | Open Access
 
This paper looks to be of importance, particularly given DecodeME’s identification of synapse-related genes.

Before delving into findings some framing through the paper is notable.

Cog-LC is considered a major burden not only to individuals’ daily activities but also in the global socioeconomic context, estimated at approximately one trillion dollars

cognitive impairment (Cog-LC) is particularly challenging to characterize objectively. Currently, the diagnosis of Cog-LC relies primarily on self-reported symptoms, without established biomarkers to confirm or stratify the condition. This lack of objective diagnostic tools has contributed to under-recognition in clinical practice, delayed intervention and increased patient burden.

The target population demonstrated a slight increase in depression, MADRS, and HAM-D scores, suggesting that the global upregulation of AMPAR may not be exclusively attributable to cognitive impairment. However, depressive symptoms in this population did not meet the diagnostic criteria for major depressive disorder, as defined by the DSM-5 or ICD-10, and were instead subclinical symptoms secondary to cognitive impairment.

we distinguished the [11C]K-2 PET imaging of participants with Cog-LC and HCs with high sensitivity and specificity. Therefore, [11 C]K-2 PET imaging holds promise as a robust diagnostic tool for Cog-LC, particularly in cases of challenging diagnoses and when patients may not receive adequate medical support despite experiencing symptoms.

Future clinical and biological studies should elucidate similar post-viral cognitive impairments and myalgic encephalomyelitis/chronic fatigue syndrome to deepen our understanding of the interactions between the immune and nervous systems.
 
Last edited:
Just when you think everyone’s tried every medication not seeing any hits on old forums or Reddit for anyone trying the suggested therapeutic Perampanel.
 
Just when you think everyone’s tried every medication not seeing any hits on old forums or Reddit for anyone trying the suggested therapeutic Perampanel.




 
“Therefore, the upregulated [¹¹C]K-2 SUVRWM in patients with Cog-LC may indicate increased surface-expressed AMPAR density. Therefore, non-competitive antagonists of AMPAR, such as perampanel, may be a therapeutic candidate for Cog-LC. This should be tested in future randomized controlled trials.”

Maybe this is the only available non-competitive AMPAR antagonist?
 
Press release:

Uncovering the Molecular Basis of Long COVID Brain Fog​

2025.10.01
Researcher(s): Takuya Takahashi, Hiroki Abe, Tsuyoshi Eiro

Researchers use a specialized brain imaging technique to identify a potential biomarker and therapeutic target of Long COVID

Long COVID is a chronic condition that causes cognitive problems known as “brain fog,” but its biological mechanisms remain largely unclear. Now, researchers from Japan used a novel imaging technique to visualize AMPA receptors—key molecules for memory and learning—in the living brain. They discovered that higher AMPA receptor density in patients with Long COVID was closely tied to the severity of their symptoms, highlighting these molecules as potential diagnostic biomarkers and therapeutic targets.​

Even though many years have passed since the start of the COVID-19 pandemic, the effects of infection with SARS-CoV-2 are not completely understood. This is especially true for Long COVID, a chronic condition that can develop after COVID-19 that causes a variety of lasting symptoms. Among the most common and debilitating of these is cognitive impairment, often referred to as “brain fog,” which affects over 80% of people with Long COVID. Given the hundreds of millions of global cases, Long COVID represents a massive public health and socioeconomic challenge, as it severely impacts people’s ability to work and perform daily activities.

Unfortunately, despite its prevalence, the underlying causes of Long COVID and brain fog remain poorly understood. Previous imaging studies have shown some structural changes in the brain, but they could not pinpoint the molecular dysfunctions responsible for the cognitive symptoms. Since it’s difficult to observe the molecules that govern communication between brain cells directly, researchers are left without objective biomarkers to confirm a Long COVID diagnosis or develop therapies.

To address this challenge, a research team led by Professor Takuya Takahashi from the Graduate School of Medicine at Yokohama City University, Japan, has made a significant breakthrough in understanding the cause of Long COVID brain fog. As explained in their paper, published in Brain Communications on October 01, 2025, the team hypothesized that patients with brain fog might exhibit disrupted expression of AMPA receptors (AMPARs)—key molecules for memory and learning—based on prior research into psychiatric and neurological disorders such as depression, bipolar disorder, schizophrenia, and dementia. Thus, they used a novel method called [11C]K-2 AMPAR PET imaging to directly visualize and quantify the density of AMPARs in the living human brain.

By comparing imaging data from 30 patients with Long COVID to 80 healthy individuals, the researchers found a notable and widespread increase in the density of AMPARs across the brains of patients. This elevated receptor density was directly correlated with the severity of their cognitive impairment, suggesting a clear link between these molecular changes and the symptoms. Additionally, the concentrations of various inflammatory markers were also correlated with AMPAR levels, indicating a possible interaction between inflammation and receptor expression.

Taken together, the study’s findings represent a crucial step forward in addressing many unresolved issues regarding Long COVID. The systemic increase in AMPARs provides a direct biological explanation for the cognitive symptoms, highlighting a target for potential treatments. For example, drugs that suppress AMPAR activity could be a viable approach to mitigate brain fog. Interestingly, the team’s analysis also demonstrated that imaging data can be used to distinguish patients from healthy controls with 100% sensitivity and 91% specificity. “By applying our newly developed AMPA receptor PET imaging technology, we aim to provide a novel perspective and innovative solutions to the pressing medical challenge that is Long COVID,” remarks Prof. Takahashi.

While further efforts will be needed to find a definitive solution for Long COVID, this work is a promising step in the right direction. “Our findings clearly demonstrate that Long COVID brain fog should be recognized as a legitimate clinical condition. This could encourage the healthcare industry to accelerate the development of diagnostic and therapeutic approaches for this disorder,” concludes Prof. Takahashi.

In summary, the team’s findings resolve key uncertainties about the biological basis of Long COVID brain fog and may pave the way for novel diagnostic tools and effective therapies for patients suffering from this condition.

Image title: Molecular brain imaging as a tool for understanding Long COVID
Image caption: These brain images show how increased levels of AMPA receptors correlate with both cognitive dysfunctions and inflammatory biomarkers.
Image credit: Professor Takuya Takahashi from Yokohama City University
License type: Original content
Usage restrictions: Cannot be reused without permission.

Reference​

Title of original paper: Systemic increase of AMPA receptors associated with cognitive impairment of Long COVID
Journal: Brain Communications
DOI: 10.1093/braincomms/fcaf337
About Professor Takuya Takahashi from Yokohama City University
Dr. Takuya Takahashi obtained a PhD from Yale University in 2000. He joined Yokohama City University in 2006, where he currently serves as a full Professor. He specializes in neuroscience and brain research, particularly in AMPA receptor synaptic migration as a molecular mechanism of synaptic plasticity, with potential for diagnostic and treatment advances in psychiatric and neurological diseases. He has published over 60 papers on these topics.
Funding information
This clinical trial project was supported by donations from the READYFOR crowdfunding platform (https://readyfor.jp/). This project was partially supported by Takeda Science Foundation (T.T.), the Japan Agency for Medical Research and Development (AMED) under grant numbers JP24wm0625304 (T.T.), and JST through the Establishment of University Fellowships Towards the Creation of Science Technology Innovation program, under grant JPMJFS2140 (Y.F.).
Link to full article

For inquiries regarding this press release​

Takuya Takahashi
Professor
Department of Physiology, Graduate School of Medicine
Yokohama City University

Media contact​

Yokohama City University, Public Relations Division
koho@yokohama-cu.ac.jp


 
Last edited:
The target population demonstrated a slight increase in depression, MADRS, and HAM-D scores, suggesting that the global upregulation of AMPAR may not be exclusively attributable to cognitive impairment. However, depressive symptoms in this population did not meet the diagnostic criteria for major depressive disorder, as defined by the DSM-5 or ICD-10, and were instead subclinical symptoms secondary to cognitive impairment.
Those are useless anyway, the impairment and impact of brain fog almost perfectly overlap with depression questionnaires. Not depression itself, just the questionnaires. Everything depends on how the questions are interpreted by the patients.

Same reason why comparing to such cohorts is equally useless, their data set are largely polluted by invalid cases because of that overlap. At least here they seem to have somewhat the right conclusion, although I don't think I have once seen any health care professional correctly get it that any such 'depression' is not actually some psychological reaction to the underlying illness, but rather they are incorrectly attributing those consequences as being some separate disorder, like diagnosing people sick with the flu with melancholia because they're wasting in bed.

It's so demoralizing to think of how quickly progress could be made if the invalid biases that corrupt all medical research were removed from the board. That's all it would take to generate breakthroughs, because even when a few people get the conclusion mostly right, the vast majority interpret it in the traditional ways, leading everything nowhere.
Future clinical and biological studies should elucidate similar post-viral cognitive impairments and myalgic encephalomyelitis/chronic fatigue syndrome to deepen our understanding of the interactions between the immune and nervous systems.
And it's ironic how it's also so demoralizing how despite all the junk about being 'holistic', no one in this profession ever sees to manage to think big picture. Brain fog is a huge problem, found in all sorts of health problems, it is not at all restricted to chronic illnesses. But because 'holistic' has become to explicitly mean pseudoscientific woo, it's as if no one can because the whole concept has been wasted.

I'm very skeptical of the whole "memory and learning" aspect, though. Brain fog limits learning and impairs memory, but it can switch on or off in a matter of seconds. Impairment in learning and memory are not switched on or off on that time scale. But that's also something where no one seems able to pull off thinking about the big picture.
 
Brain fog limits learning and impairs memory, but it can switch on or off in a matter of seconds. Impairment in learning and memory are not switched on or off on that time scale.
That's what caught my attention in that study too. My brainfog doesn't seem to cause memory problems. I haven't properly tested my ability to learn during brainfog vs no brainfog, but haven't noticed any dramatic difference.

I doubt that they have a deep understanding of what AMPAR does, so maybe it does affect brainfog rather than just memory/learning.
 
What’s so incredible about this potential dx biomarker is they got 100% sensitivity and 91% selectivity, I don’t think I’ve seen any ME/LC research biomarker do so well
Almost a little too good.

But the inclusion criteria seem very strict so perhaps this will stand:
Patients aged 20–59 years with subjective cognitive impairment as sequelae of SARS-CoV-2 infection and no previous history of neuropsychiatric disorders were recruited. The inclusion criteria were as follows: (i) male or female, aged 20–59 years at the time of consent; (ii) confirmed SARS-CoV-2 infection through clinical symptoms (e.g. fever and upper respiratory symptoms) diagnosed by a physician or positive polymerase chain reaction (PCR) or antigen test at a medical institution; (iii) persistent cognitive sequelae lasting for at least 2 months<span></span><a data-open="fcaf337-B38" data-google-interstitial="false">38</a> with ongoing symptoms affecting work, study, or daily life at the time of consent; (iv) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score<span></span><a data-open="fcaf337-B39" data-google-interstitial="false">39</a> below 85 after age adjustment (mean 100, SD 15) or a subscale score of ≤−1 SD; and (v) deemed competent to provide consent based on the MacArthur Competence Assessment Tool (MacCAT) evaluation, with written consent obtained from the participants or their legal representatives. The study cohort did not include individuals with a prior history of medical or neurological conditions associated with cognitive impairment. Screening for a history of neuropsychiatric disorders was conducted through clinical interviews performed by both a board-certified psychiatrist and a neurologist. In addition, the Autism Spectrum Quotient (AQ) and Part III of the MDS-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS Part III) were administered as supportive assessments.
 
Almost a little too good.

But the inclusion criteria seem very strict so perhaps this will stand:
Could it be a case of selecting a very narrow group of patients so you’re more likely to get good separation?

Patients that didn’t score abnormally on the cognitive tests were excluded. If they are anything like the tests I did at the start of my illness, I would not have been included even though my brainfog was terrible.

I can imagine a situation with a lot of false negatives (low sensitivity) for many with brainfog issues or only brainfog when in PEM.
 
Just when you think everyone’s tried every medication not seeing any hits on old forums or Reddit for anyone trying the suggested therapeutic Perampanel.

Coincidentally announced today is FDA approval for a phase 2 study on AMPAR modulation from a Welsh biotech.

Cardiff, United Kingdom – 2 October 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces that it will initiate a Phase 2 study of DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM) for Major Depressive Disorder (MDD) in the US in Q4 2025. The decision follows US Food and Drug Administration (FDA) clearance of the IND application for the Phase 2 trial protocol.

Note that this is upregulating AMPAR function, impaired in depression. See https://en.wikipedia.org/wiki/AMPA_receptor_positive_allosteric_modulator
 
Back
Top Bottom